Ankylosing Spondylitis Market Expected to Reach $8.1 Billion by 2030

According to a new report published by Allied Market Research, titled, “Ankylosing Spondylitis Market by Drug Class, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021–2030," the ankylosing spondylitis market size was valued at $5,140.94 million in 2020, and is projected to reach $8,110.59 million by 2030, registering a CAGR of 4.6% from 2021 to 2030.

Ankylosing spondylitis is a chronic inflammatory disease that affects the spine. It is a type of arthritis, in which spine bones grow or fuse together, causing the spine to become rigid. Symptoms of ankylosing spondylitis include pain and stiffness from the neck to the lower back, bony fusion, and pain in the ligaments and tendons. These symptomatic changes may be mild or severe, and may lead to a stooped-over posture.

The cause of ankylosing spondylitis is not discovered yet, however it has been linked with a gene called HLA-B27. It has been observed that some patients are carrying same gene i.e. HLA-B27. Ankylosing spondylitis can be diagnosed via X-rays of the back and pelvis; or by physical examination.

Factors that drive the growth of the ankylosing spondylitis market include rise in number of hospitals, increase in ankylosing spondylitis patients and advancement in ankylosing spondylitis treatment and surgery. For instance, according to World Health Organization (WHO), in 2021, musculoskeletal conditions are the leading contributor to disability worldwide, with low back pain being the single leading cause of disability in 160 countries. Furthermore, rise in awareness about ankylosing spondylitis contributes toward growth of the ankylosing spondylitis market.

The ankylosing spondylitis market is segmented into by drug class, distribution channel and region.

On the basis of drug class, the market is divided into NSAIDs, TNF inhibitors and others. The NSAIDs segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in number patients suffering from ankylosing spondylitis and high reliability of product.

By distribution channel market is divided into hospitals pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominates the ankylosing spondylitis market in 2020, and this trend is expected to continue during the forecast period, and high prevalence of ankylosing spondylitis.

North America accounted for a majority of the global ankylosing spondylitis market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to presence of key players in the region. Asia-Pacific is anticipated to witness lucrative growth, owing to increase in number of ankylosing spondylitis patients.

The COVID-19 outbreak is anticipated to have a negative impact on the growth of the ankylosing spondylitis market as most of the hospitals are not operating on outpatients due to COVID-19, there is implementation of lockdown in many countries. The COVID-19 virus had serious and life-threatening impact on patients with vascular disorders. Hence, to avoid COVID-19 virus infection spread and risk for patients, many of the orthopedic surgeries have either been canceled or postponed. In addition, wave of COVID-19 spread has created burden on hospitals, resulting in many surgeries being postponed and having longer waiting time. For instance, according to a report by British Broadcasting Corporation (BBC), due to second wave of COVID-19, around 4.7 million people were waiting for routine operations and procedures in England in Feb, 2021.

Key Findings Of The Study

• On the basis of drug class, the NSAIDs segment was the highest contributor to the ankylosing spondylitis market in 2020.
• By distribution channel, retail pharmacy segment dominated the market in 2020.
• Region wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period